Roche Blocks Indian Trastuzumab, Claiming No Room For ‘Uncertainty’
This article was originally published in PharmAsia News
Executive Summary
Roche has moved to block Reliance's biosimilar version of its anticancer Herceptin in India, citing “genuine” concern over the comparable safety and efficacy of the Indian firm's product.